Comparative Pharmacology
Head-to-head clinical analysis: COREG versus PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
Head-to-head clinical analysis: COREG versus PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
COREG vs PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carvedilol is a nonselective beta-blocker with alpha1-blocking activity. It competitively blocks beta1, beta2, and alpha1 adrenergic receptors, leading to decreased cardiac output, reduced sympathetic tone, and vasodilation. It also has antioxidant and anti-proliferative properties.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Heart failure: Start 3.125 mg orally twice daily; titrate up to target 25 mg twice daily as tolerated. Hypertension: Start 6.25 mg orally twice daily; increase to max 50 mg twice daily. Post-MI LV dysfunction: Start 3.125-6.25 mg orally twice daily; titrate to target 25 mg twice daily.
Oral: 1 tablet (propranolol 40 mg / hydrochlorothiazide 25 mg) twice daily or as needed to control blood pressure; maximum propranolol 320 mg/day.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours in most patients, but may be prolonged in severe hepatic impairment (up to 14-18 hours). The half-life is not significantly altered in renal impairment.
Propranolol: 3-6 hours (terminal) with significant interindividual variability; prolonged in hepatic impairment (up to 11 hours). Hydrochlorothiazide: 6-15 hours (terminal); prolonged in renal impairment (creatinine clearance <30 mL/min).
Renal excretion of unchanged drug and metabolites accounts for approximately 16% of the dose; fecal excretion accounts for about 84% (mainly as metabolites). Less than 2% is excreted unchanged in urine.
Propranolol: <1% unchanged in urine; extensively metabolized in liver, metabolites (4-hydroxypropanolol and others) excreted renally (90%) and fecally (10%). Hydrochlorothiazide: >95% renally excreted unchanged; negligible biliary/fecal elimination.
Category C
Category C
Beta-Blocker
Beta-Blocker